Shares of Mainz Biomed B.V. (MYNZ) surged over 40% on Wednesday morning after the molecular genetics diagnostic company announced that it acquired exclusive rights to novel mRNA biomarkers.
MYNZ is currently trading at $14.76, up $4.44 or 43.02%, on the Nasdaq.
Mainz Biomed has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert, the company's highly efficacious, and easy-to-use detection test for colorectal cancer.
Mainz is currently marketing ColoAlert in Europe through its unique business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. The Company is also preparing to initiate ColoAlert's regulatory pathway for approval in the United States.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.